Celiac Disease — Experiences of Disclosure in Adolescents With Coeliac Disease
Citation(s)
Ashton, K , Myers, S., Whitehead, E., & Sebastian, S. (2016). OC-058 Perspectives of Adolescent IBD Patients Undergoing Surgery. Gut, 65, A34. doi: 10.1136/gutjnl-2016-312388.57
Barratt SM, Leeds JS, Sanders DS Factors influencing the type, timing and severity of symptomatic responses to dietary gluten in patients with biopsy-proven coeliac disease. J Gastrointestin Liver Dis. 2013 Dec;22(4):391-6.
Green PH, Jabri B Celiac disease. Annu Rev Med. 2006;57:207-21. Review.
Green PH, Jabri B Coeliac disease. Lancet. 2003 Aug 2;362(9381):383-91. Review.
Gulliver A, Griffiths KM, Christensen H Perceived barriers and facilitators to mental health help-seeking in young people: a systematic review. BMC Psychiatry. 2010 Dec 30;10:113. doi: 10.1186/1471-244X-10-113. Review.
NICE (2015). Clinical Guidelines: Coeliac Disease Recognition, assessment and management: Methods, evidence and recommendations (Standard No. NG20). Retrieved from https://www.nice.org.uk/guidance/ng20/evidence/Full guidance-pdf- 438530077
Olsson C, Lyon P, Hörnell A, Ivarsson A, Sydner YM Food that makes you different: the stigma experienced by adolescents with celiac disease. Qual Health Res. 2009 Jul;19(7):976-84. doi: 10.1177/1049732309338722.
Rickwood DJ, Deane FP, Wilson CJ When and how do young people seek professional help for mental health problems? Med J Aust. 2007 Oct 1;187(S7):S35-9. Review.
Rutter, M , & Smith, D.J. (1995). Psychosocial Disorders in Young People: Time Trends and Their Causes. Chicester: John Wiley & Lons Ltd.
Schroeder, R D., & Mowen, T. J. (2014). "You Can't Eat WHAT?" Managing the Stigma of Celiac Disease. Deviant Behavior, 35(6), 456-474. doi: 10.1080/01639625.2014.855105
Smith, J A., Flowers, P., & Larkin, M. (2009). Interpretative phenomenological analysis: Theory, method and research. London: Sage.
Understanding Perceived Barriers to the Disclosure of Psychological Difficulties by Young People With Coeliac Disease
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
